SRDX Earnings

SRDX reported its earnings on 2025-11-19, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.19 by 0% . The stock experienced a 0.16% price change on the earnings day and a -0.56% change over the next five days, reflecting market reactions to the results.

Following SRDX's earnings announcement on 2025-11-19, the stock price moved by 0.16% on the day of the release. Over the subsequent five days, it saw a -0.56% change. Historically, SRDX's stock price tends to shift by an average of -2.53% in the 10 days leading up to earnings and +1.91% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate SRDX’s annual revenue to reach 30.14M, while the EPS is projected at -0.18. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SRDX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SRDX's stock price typically moves by -2.53% in the 10 days before its earnings and +1.91% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.18 and revenue of 30.14M.

The earnings call summary indicates strong product sales growth, particularly in the Vascular Interventions portfolio, and a positive response to new product launches. Despite a decrease in IVD revenue, overall financial guidance for fiscal 2024 remains optimistic, with expected revenue growth and cash flow improvements. The partnership with Abbott and consistent demand for SurVeil DCB further support a positive outlook. However, management's reluctance to provide specific details and guidance on international sales may temper expectations slightly, resulting in a 'Positive' sentiment rating.